These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28797193)

  • 1. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
    Parikh A; Gopalakrishnan S; Freise KJ; Verdugo ME; Menon RM; Mensing S; Salem AH
    Leuk Lymphoma; 2018 Apr; 59(4):871-879. PubMed ID: 28797193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
    Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
    J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
    de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
    Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
    Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
    Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
    Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
    Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
    Davids MS; Roberts AW; Kenkre VP; Wierda WG; Kumar A; Kipps TJ; Boyer M; Salem AH; Pesko JC; Arzt JA; Mantas M; Kim SY; Seymour JF
    Clin Cancer Res; 2021 Sep; 27(17):4690-4695. PubMed ID: 34083230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
    Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
    Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
    Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
    Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
    Konopleva M; Pollyea DA; Potluri J; Chyla B; Hogdal L; Busman T; McKeegan E; Salem AH; Zhu M; Ricker JL; Blum W; DiNardo CD; Kadia T; Dunbar M; Kirby R; Falotico N; Leverson J; Humerickhouse R; Mabry M; Stone R; Kantarjian H; Letai A
    Cancer Discov; 2016 Oct; 6(10):1106-1117. PubMed ID: 27520294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.